CL2020001009A1 - Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos. - Google Patents
Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos.Info
- Publication number
- CL2020001009A1 CL2020001009A1 CL2020001009A CL2020001009A CL2020001009A1 CL 2020001009 A1 CL2020001009 A1 CL 2020001009A1 CL 2020001009 A CL2020001009 A CL 2020001009A CL 2020001009 A CL2020001009 A CL 2020001009A CL 2020001009 A1 CL2020001009 A1 CL 2020001009A1
- Authority
- CL
- Chile
- Prior art keywords
- substituted heterocyclic
- amine
- salts
- heterocyclic compounds
- synthesis methods
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000001308 synthesis method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- -1 amine substituted heterocyclic compounds Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573917P | 2017-10-18 | 2017-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001009A1 true CL2020001009A1 (es) | 2020-12-18 |
Family
ID=66173899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001009A CL2020001009A1 (es) | 2017-10-18 | 2020-04-15 | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200247790A1 (enExample) |
| EP (1) | EP3697762A4 (enExample) |
| JP (2) | JP2021500334A (enExample) |
| KR (1) | KR20200101330A (enExample) |
| CN (1) | CN111417628A (enExample) |
| AU (2) | AU2018353122B2 (enExample) |
| BR (1) | BR112020007632A2 (enExample) |
| CA (1) | CA3079273A1 (enExample) |
| CL (1) | CL2020001009A1 (enExample) |
| CO (1) | CO2020005944A2 (enExample) |
| EA (1) | EA202090959A1 (enExample) |
| IL (2) | IL301746B2 (enExample) |
| MA (1) | MA50418A (enExample) |
| MX (2) | MX2020007152A (enExample) |
| SG (1) | SG11202003225YA (enExample) |
| WO (1) | WO2019079540A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11225486B2 (en) | 2017-10-18 | 2022-01-18 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
| US12173006B2 (en) | 2018-09-05 | 2024-12-24 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110446495B (zh) | 2017-02-17 | 2023-09-05 | 特维娜有限公司 | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
| US11672800B2 (en) | 2017-04-21 | 2023-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
| JP2023546729A (ja) * | 2020-10-27 | 2023-11-07 | トレベナ・インコーポレイテッド | デルタオピオイドモジュレーターの結晶形及び非晶形 |
| WO2025240956A1 (en) * | 2024-05-17 | 2025-11-20 | Yale University | G9a/ehmt2 inhibitor use for prader-willi syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505858A (ja) * | 2003-09-18 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン |
| NZ592990A (en) * | 2005-11-01 | 2013-01-25 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| ES2769648T3 (es) * | 2014-06-16 | 2020-06-26 | Fundacion Para La Investig Medica Aplicada | Nuevos compuestos como inhibidores duales de histona metiltransferasas y ADN metiltransferasasASAS |
| US20170209444A1 (en) * | 2014-06-23 | 2017-07-27 | Genentech Inc. | Methods of treating cancer and preventing cancer drug resistance |
| LT3442947T (lt) * | 2016-04-15 | 2023-09-11 | Epizyme, Inc. | Aminu pakeisti arilo arba heteroarilo junginiai, kaip ehmt1 ir ehmt2 inhibitoriai |
| TW202411220A (zh) * | 2016-12-19 | 2024-03-16 | 美商雅酶股份有限公司 | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| EP3697420A4 (en) * | 2017-10-18 | 2021-11-24 | Epizyme, Inc. | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES |
-
2018
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en active Active
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en not_active Ceased
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en not_active Withdrawn
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11225486B2 (en) | 2017-10-18 | 2022-01-18 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
| US11926630B2 (en) | 2017-10-18 | 2024-03-12 | Incyte Corporation | Tertiary alcohols as PI3K-γ inhibitors |
| US12173006B2 (en) | 2018-09-05 | 2024-12-24 | Incyte Corporation | Crystalline forms of a phosphoinositide 3-kinase (PI3K) inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220324851A1 (en) | 2022-10-13 |
| IL301746B1 (en) | 2024-09-01 |
| SG11202003225YA (en) | 2020-05-28 |
| AU2018353122B2 (en) | 2023-11-23 |
| CA3079273A1 (en) | 2019-04-25 |
| EA202090959A1 (ru) | 2020-07-13 |
| MX2024012124A (es) | 2025-02-10 |
| IL273974B2 (en) | 2023-08-01 |
| KR20200101330A (ko) | 2020-08-27 |
| EP3697762A4 (en) | 2021-04-07 |
| IL301746B2 (en) | 2025-01-01 |
| MA50418A (fr) | 2021-04-07 |
| CO2020005944A2 (es) | 2020-07-31 |
| JP2021500334A (ja) | 2021-01-07 |
| IL273974B1 (en) | 2023-04-01 |
| MX2020007152A (es) | 2020-12-10 |
| WO2019079540A1 (en) | 2019-04-25 |
| US20200247790A1 (en) | 2020-08-06 |
| AU2024201165A1 (en) | 2024-03-14 |
| IL301746A (en) | 2023-05-01 |
| IL273974A (en) | 2020-05-31 |
| BR112020007632A2 (pt) | 2020-09-29 |
| JP2023036991A (ja) | 2023-03-14 |
| EP3697762A1 (en) | 2020-08-26 |
| AU2018353122A1 (en) | 2020-06-04 |
| CN111417628A (zh) | 2020-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001009A1 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos. | |
| CO2019006787A2 (es) | Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos | |
| MX384521B (es) | Compuestos de benceno substituidos con arilo o heteroarilo. | |
| MX2015004771A (es) | Metodos para tratar cancer. | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| EA201592068A1 (ru) | Ингибиторы энхансера zeste гомолога 2 | |
| CL2016001790A1 (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2. | |
| MX2018008052A (es) | Inhibidores de desmetilasa especifica de lisina 1 (lsd1). | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| MX2020011104A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| MX379155B (es) | Compuestos que inhiben la proteína mcl-1. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
| AR100431A1 (es) | Compuestos de pladienolida piridina y métodos de uso | |
| TR201908265T4 (tr) | Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri. | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| BR112017028616A2 (pt) | acentuador de inibidores de homólogo de zeste 2 | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| MX2018002898A (es) | Compuestos utiles para inhibir ror-gamma-t. | |
| UY37191A (es) | Derivados de dibenzofurano para uso como inhibidores de bromodominio | |
| EA201892539A1 (ru) | Пиридинильные производные, фармацевтические композиции и их применение в качестве ингибиторов аос3 | |
| AR105400A1 (es) | Inhibidores de jak1 |